Mon, Sep 22, 2014, 9:11 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Coca-Cola Enterprises Inc. Message Board

jklong59 4 posts  |  Last Activity: Aug 7, 2014 1:07 PM Member since: Jun 9, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    infliximab ?

    by jklong59 Aug 5, 2014 1:39 PM jklong59 Aug 7, 2014 1:07 PM Flag

    Would you know if BOW015 was approved in the USA or Europe And if in Europe have they made any plans to manufacture? I see it is a billion dollar market and that at least one other company has been approved but are dealing with patents.

  • Reply to

    Messa. What is next?..

    by darviris_99 Jul 28, 2014 3:05 PM jklong59 Aug 7, 2014 12:45 PM Flag

    What I can not understand is why liberals call republicans racist when it was the republicans that freed the slaves. But like you said they do not deal well with facts.

  • Reply to

    EPRS silent since merger

    by gmegga Aug 5, 2014 9:15 PM jklong59 Aug 6, 2014 12:23 PM Flag

    It appears to be a secret. An approved product but no hints on commercialization, possibly due to patents. And no info on the old zlcs pipeline. It seems they could be a bit more transparent on what is going on.

  • by jklong59 Aug 5, 2014 1:39 PM Flag

    I see that EPIRUS has a product that is a biosimilar called BOW015 a biosimilar for Infliximab that has been approved. Can it be marketed or is there patent issues? I did some research and found that other companies also have a biosimilar for Infliximab but have not seen where it is marketed anywhere possibly due to patent issues. The Epirus website supplies very little information.

46.12-0.15(-0.32%)Sep 22 4:01 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.